VERAXA Biotech (NASDAQ: VRXA), a company focused on developing novel cancer therapies, has released new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology aimed at improving the selectivity of antibody-drug conjugates in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).
The company reported that its BiTAC-ADC technology demonstrated selective activity against cancer cells while sparing healthy cells in early testing. Specifically, the platform was able to distinguish between breast cancer cells and healthy cells in laboratory studies and showed dose-dependent destruction of three-dimensional tumor cell spheroids. These results suggest the potential for a more targeted approach to cancer therapy, reducing the off-target effects that often limit traditional antibody-drug conjugates.
VERAXA’s proprietary BiTAC (Bispecific T-cell Activating Complex) approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells. The company is presenting both its BiTAC-ADC and BiTAC-TCE (T-cell engager) platforms at the BIO convention, seeking strategic collaborations to advance these technologies toward clinical development.
The company maintains a diversified oncology pipeline of antibody-based formats, including antibody-drug conjugates, T-cell engagers, and other antibody-based formats. VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp.
While the BiTAC-ADC platform remains in early development, the results provide a foundation for further preclinical studies and potential partnerships. The company’s presence at BIO International Convention 2026 underscores its commitment to advancing next-generation cancer therapies through collaboration. Forward-looking statements regarding the platform’s potential are subject to risks and uncertainties, as detailed in the company’s filings with the SEC, available at http://IBN.fm/Disclaimer. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
